177Lu-PSMA-617 is a radioligand with high affinity for prostate-specific membrane antigen
(PSMA), enabling targeted β-irradiation of prostate cancer. We have previously reported …

Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy
of metastasized castration-resistant prostate cancer (mCRPC). Besides high affinity and long …

Aims There is a controversy as to the relative efficacy of 177 Lu prostate specific membrane
antigen (PSMA) radioligand therapy (RLT) and third-line treatment for patients with …

177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy
(RLT) of patients with metastatic castration-resistant prostate cancer (mCRPC). Initiated by …

Purpose Preliminary data from retrospective analyses and recent data from large
randomized controlled trials suggest safety and efficacy of radioligand therapy (RLT) …

Background Metastatic castration-resistant prostate cancer remains fatal despite recent
advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic …

177Lu-labeled prostate-specific membrane antigen (PSMA) radioligand therapy using
PSMA-617 and PSMA-I&T ligands (177Lu-PRLT) is an emerging treatment in metastatic …

Background Progressive metastatic castration-resistant prostate cancer is a highly lethal
disorder and new effective therapeutic agents that improve patient outcomes are urgently …

Background Despite progress in treatment of metastatic castration-resistant prostate cancer
(mCRPC), new approaches are urgently needed. Recently theranostic concepts using …

Prostate cancer can be targeted by ligands to the prostate-specific membrane antigen
(PSMA). We aimed to evaluate dosimetry, safety and efficacy of 177 Lu-PSMA-617 …